Karyopharm Announces the Appointment of Peter K Honig, MD, MPH to its Board of Directors

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the...

Related Keywords

China ,Boston ,Massachusetts ,United States ,Japan ,American ,Mikael Dolsten ,Peterk Honig ,Barrye Greene ,Office Of Drug Safety ,Alopexx Enterprises ,Drug Information Association ,American Society For Clinical Pharmacology ,Nasdaq ,Medicine Consortium ,Pfizer ,Astrazeneca ,Head Of Global Regulatory Affairs ,Karyopharm Selective Inhibitor Of Nuclear Export ,European Union ,Karyopharm Therapeutics Inc ,Merck Research Laboratories ,International Conference On Harmonisation ,Steering Committee ,Drug Administration ,European Commission ,Columbia University ,Prnewswire Karyopharm Therapeutics Inc ,Exchange Commission ,Group Head Of Development ,Centre Of Regulatory Excellence ,Lead Director ,Senior Vice President ,Global Regulatory Affairs ,Group Head ,Drug Safety ,Drug Evaluation ,International Conference ,American Society ,Clinical Pharmacology ,Sesen Bio ,Regulatory Excellence ,Accelerating Therapeutics ,Scientific Advisory Board ,Selective Inhibitor ,Nuclear Export ,Private Securities Litigation Reform Act ,Quarterly Report ,Karyopharm Therapeutics ,